Stockwatch: Biotech Triggers Its Own Sell-Off
This article was originally published in Scrip
Executive Summary
Last week, second-quarter earnings season degenerated not just into the long tail of loss-making companies reporting, well, their losses, but into a savage sell-off that even took the shine off the good news. Stock market commentators will look to various factors to explain the sell-off, but this time there is no single underlying cause. It was triggered by a set of independent, unconnected and cumulative events.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.